tm2622018-3_424b5 - none

424B5 1 tm2622018-3_424b5.htm 424B5 tm2622018-3_424b5 - none - 4.9843994s

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-296897

PROSPECTUS SUPPLEMENT
(To Prospectus dated June 18, 2026)

3,125,000 Shares

Common Stock

Twist Bioscience Corporation is offering 3,125,000 shares of its common stock.

Our common stock is listed and trades on the Nasdaq Global Select Market under the symbol “TWST.” On August 4, 2026, the last reported sale price on Nasdaq of our common stock on the Nasdaq Global Select Market was $99.44 per share.

Investing in our common stock involves risks. See the section titled “Risk Factors” beginning on page S-7 of this prospectus supplement, as well as in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

	Per Share			Total
Public offering price		$	96.00		$	300,000,000
Underwriting discounts and commissions(1)		$	4.80		$	15,000,000
Proceeds, before expenses, to Twist Bioscience Corporation		$	91.20		$	285,000,000

(1)

See the section titled “Underwriting” for a description of the compensation payable to the underwriters.

We have granted the underwriters an option for a period of 30 days to purchase up to 468,750 additional shares of our common stock at the public offering price less underwriting discounts and commissions.

The underwriters expect to deliver the shares against payment in New York, New York on or about August 6, 2026.

Goldman Sachs & Co. LLC

William Blair

Leerink Partners

Guggenheim Securities

Prospectus Supplement dated August 4, 2026

	Page
ABOUT THIS PROSPECTUS SUPPLEMENT		S-1
PROSPECTUS SUMMARY		S-3
THE OFFERING		S-5
RISK FACTORS		S-7
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS		S-10
USE OF PROCEEDS		S-12
DILUTION		S-13
DIVIDEND POLICY		S-15
MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS		S-16
UNDERWRITING		S-20
LEGAL MATTERS		S-29
EXPERTS		S-29
WHERE YOU CAN FIND MORE INFORMATION		S-29
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE		S-30

	Page
ABOUT THIS PROSPECTUS		1
PROSPECTUS SUMMARY		2
RISK FACTORS		4
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS		5
USE OF PROCEEDS		7
SELLING SECURITYHOLDERS		8
DESCRIPTION OF OUR CAPITAL STOCK		9
DESCRIPTION OF OUR DEBT SECURITIES		12
DESCRIPTION OF OUR WARRANTS		13
DESCRIPTION OF OUR UNITS		14
PLAN OF DISTRIBUTION		15
LEGAL MATTERS		17
EXPERTS		17
WHERE YOU CAN FIND ADDITIONAL INFORMATION		17
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE		18

(In thousands)	Three months ended June 30, 2026
GAAP net (loss) income		$	(35,051)
Add (Deduct) adjustments:
Interest income		$	(1,500)
Income tax expense			311
Depreciation and amortization			6,778
EBITDA		$	(29,462)
Add (Deduct) adjustments:
Other (income) expense, net			(40)
Stock-based compensation expense			18,176
Adjusted EBITDA		$	(11,326)

Public offering price per share			$	96.00
Unaudited net tangible book value per share of our common stock as of June 30, 2026	$	5.60
Increase in unaudited net tangible book value per share of our common stock attributable to investors in this offering	$	4.06
As adjusted unaudited pro forma net tangible book value per share as of June 30, 2026, immediately after this offering			$	9.65
Dilution per share to new investors participating in this offering			$	86.35

Underwriter	Number of Shares
Goldman Sachs & Co. LLC		1,406,250
William Blair & Company, L.L.C.		625,000
Leerink Partners LLC		625,000
Guggenheim Securities, LLC		468,750
Total		3,125,000

	No Exercise			Full Exercise
Per Share		$	4.80		$	4.80
Total		$	15,000,000		$	17,250,000